GLP 1 Education Center

Want to dive into the clinical studies to get a deeper understanding?

Semaglutide — STEP 1 (NEJM, 2021)
Adults with overweight/obesity (no diabetes) on semaglutide 2.4 mg weekly lost ~15% body weight over 68 weeks vs ~2% on placebo, with lifestyle support.
View RCT (NEJM)
Semaglutide — STEP 4 Withdrawal (JAMA, 2021)
After a run-in to 2.4 mg, continuing semaglutide for 48 weeks led to further weight loss; switching to placebo led to weight regain—supporting ongoing therapy for maintenance.
View RCT (JAMA)
Semaglutide — SELECT CV Outcomes (NEJM, 2023)
In adults with overweight/obesity and established cardiovascular disease (without diabetes), semaglutide reduced major adverse cardiovascular events vs placebo.
View RCT (NEJM)
Tirzepatide — SURMOUNT-1 (NEJM, 2022)
Adults with obesity/overweight (no diabetes) achieved ~15–21% mean weight loss at 72 weeks with once-weekly tirzepatide vs placebo, alongside lifestyle measures.
View RCT (NEJM)
Tirzepatide — SURMOUNT-4 Maintenance (JAMA, 2024)
Participants who continued tirzepatide maintained and improved weight loss; those switched to placebo regained—underscoring the value of continued treatment.
View RCT (JAMA)
Tirzepatide vs Semaglutide — Head-to-Head (NEJM, 2025)
A direct comparison in adults with obesity found tirzepatide produced greater reductions in body weight and waist circumference vs semaglutide at 72 weeks.
View RCT (NEJM)
`